An Overview of drug discovery efforts for eczema: why is this itch so difficult to scratch?
Publication in refereed journal


Times Cited
Altmetrics Information
.

Other information
AbstractIntroduction: Atopic dermatitis (AD) is a type of allergic/inflammatory dermatitis characterized by itch and an impairment in quality of life.

Areas covered: Herein, the authors review drug discovery efforts for AD, highlighting the clinical efficacy of novel drugs, with a particular focus on the relief of pruritus. Topical agents include emollients, topical antihistamines, corticosteroids, calcineurin inhibitors and herbs. Recently, topical phosphodiesterase E4 (PDE4) inhibitors like crisaborole have become available and are efficacious for mild to moderate AD with few side effects. For more severe AD, monoclonal antibodies like dupilumab are considered as efficacious subcutaneous treatment options. In severe and recalcitrant AD, systemic treatment can ameliorate AD symptoms.

Expert opinion: Many topical and systemic medications have demonstrated therapeutic benefits for AD. Indeed, randomized trials have shown that topical PDE4 inhibitors and subcutaneous dupilumab are safe and efficacious. Objective tools to evaluate itch and gauge treatment efficacy is important, but current methodology relies primarily on clinical scores. AD is a systemic atopic disease with a lot of complicated psychosocial issues. Suboptimal efficacy is often due to poor compliance and unrealistic expectation of curative treatment, rendering treatment difficult despite the existence of effective medications.
All Author(s) ListHon KL, Loo S, Leung AKC, Li JTS, Lee VWY
Journal nameExpert Opinion on Drug Discovery
Year2020
Month4
Volume Number15
Issue Number4
PublisherTaylor & Francis
Pages487 - 498
ISSN1746-0441
eISSN1746-045X
LanguagesEnglish-United States

Last updated on 2021-17-09 at 00:18